DK1131424T3 - Mutationer af Pakin-genet, sammensætninger, fremgangsmåder samt anvendelser - Google Patents

Mutationer af Pakin-genet, sammensætninger, fremgangsmåder samt anvendelser

Info

Publication number
DK1131424T3
DK1131424T3 DK99956079T DK99956079T DK1131424T3 DK 1131424 T3 DK1131424 T3 DK 1131424T3 DK 99956079 T DK99956079 T DK 99956079T DK 99956079 T DK99956079 T DK 99956079T DK 1131424 T3 DK1131424 T3 DK 1131424T3
Authority
DK
Denmark
Prior art keywords
gene
parkin
exons
deletion
amplifying
Prior art date
Application number
DK99956079T
Other languages
Danish (da)
English (en)
Inventor
Patrice Denefle
Sylvain Ricard
Alexis Brice
Christophe Lucking
Nacer Eddine Abbas
Sandrine Bouley
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1131424T3 publication Critical patent/DK1131424T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automatic Tape Cassette Changers (AREA)
DK99956079T 1998-11-19 1999-11-18 Mutationer af Pakin-genet, sammensætninger, fremgangsmåder samt anvendelser DK1131424T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
PCT/FR1999/002833 WO2000031253A2 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (1)

Publication Number Publication Date
DK1131424T3 true DK1131424T3 (da) 2009-11-23

Family

ID=27253486

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99956079T DK1131424T3 (da) 1998-11-19 1999-11-18 Mutationer af Pakin-genet, sammensætninger, fremgangsmåder samt anvendelser

Country Status (15)

Country Link
US (3) US8835618B2 (no)
EP (5) EP2305816A1 (no)
JP (1) JP5424519B2 (no)
AT (1) ATE440138T1 (no)
AU (1) AU778281B2 (no)
CA (1) CA2351567C (no)
CY (1) CY1110535T1 (no)
DE (1) DE69941300D1 (no)
DK (1) DK1131424T3 (no)
ES (1) ES2330281T3 (no)
IL (3) IL142755A0 (no)
NO (5) NO330896B1 (no)
NZ (1) NZ512313A (no)
PT (1) PT1131424E (no)
WO (1) WO2000031253A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (en) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenic animal model for neurodegenerative diseases
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
JP2023526449A (ja) * 2020-05-21 2023-06-21 ニスノバイオ ジーティー，エルエルシー パーキンソン病を治療するための、増加した活性を有するパーキン変異体の遺伝子治療送達

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817478A (en) * 1993-10-05 1998-10-06 Asahi Glass Company Ltd. Multicloning vector, expression vector and production of foreign proteins by using the expression vector
CN1151269C (zh) 1995-06-06 2004-05-26 扬·维吉 用于诊断性dna检测的方法
ATE315645T1 (de) 1998-02-09 2006-02-15 Boehringer Ingelheim Int Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
CA2996759A1 (fr) * 1998-11-19 2000-06-02 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations

Also Published As

Publication number Publication date
US8835618B2 (en) 2014-09-16
CA2351567C (fr) 2016-01-12
IL187652A (en) 2010-02-17
NO20012342L (no) 2001-07-18
EP2128257A3 (fr) 2010-03-03
NO20110580L (no) 2001-07-18
EP2305816A1 (fr) 2011-04-06
EP1131424B1 (fr) 2009-08-19
JP5424519B2 (ja) 2014-02-26
AU778281B2 (en) 2004-11-25
NO20110582L (no) 2001-07-18
EP2345722A1 (fr) 2011-07-20
AU1276900A (en) 2000-06-13
ES2330281T3 (es) 2009-12-07
WO2000031253A3 (fr) 2000-09-28
EP1131424A2 (fr) 2001-09-12
IL142755A (en) 2009-08-03
NO333907B1 (no) 2013-10-14
PT1131424E (pt) 2009-10-23
NO20110577L (no) 2001-07-18
NO333906B1 (no) 2013-10-14
CY1110535T1 (el) 2015-04-29
EP2128257A2 (fr) 2009-12-02
EP2311954A1 (fr) 2011-04-20
US20150074836A1 (en) 2015-03-12
NO332174B1 (no) 2012-07-16
WO2000031253A2 (fr) 2000-06-02
JP2002536961A (ja) 2002-11-05
ATE440138T1 (de) 2009-09-15
CA2351567A1 (fr) 2000-06-02
IL142755A0 (en) 2002-03-10
NO332173B1 (no) 2012-07-16
US9540693B2 (en) 2017-01-10
DE69941300D1 (de) 2009-10-01
NO20012342D0 (no) 2001-05-11
NO330896B1 (no) 2011-08-08
US20170183736A1 (en) 2017-06-29
US20120064598A1 (en) 2012-03-15
NO20110578L (no) 2001-07-18
NZ512313A (en) 2003-12-19

Similar Documents

Publication Publication Date Title
CY1110535T1 (el) Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις
Manchenko Handbook of detection of enzymes on electrophoretic gels
Townsley et al. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase
Lin et al. Increased susceptibility to UV-induced skin carcinogenesis in polymerase η–deficient mice
White et al. A roadmap for high‐throughput sequencing studies of wild animal populations using noninvasive samples and hybridization capture
WO1999043808A8 (en) Human c-maf compositions and methods of use thereof
DE69808743T2 (de) Netrinrezeptoren
JP2003517830A5 (no)
AU7286187A (en) Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
Owerbach et al. Inheritance of a parotid secretory protein in mice and its use in determining salivary amylase quantitative variants
Broome et al. Non‐invasive transgenic mouse genotyping using stool analysis
Sasaki et al. Extensive morphological convergence and rapid radiation in the evolutionary history of the family Geoemydidae (Old World pond turtles) revealed by SINE insertion analysis
Cho et al. Efficient and cost-effective non-invasive population monitoring as a method to assess the genetic diversity of the last remaining population of Amur leopard (Panthera pardus orientalis) in the Russia Far East
ATE308615T1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
ATE373095T1 (de) Mutierte muskelspezifische enhancer
EP1224861A4 (en) LARGE QUANTITIES OF A HUMAN GENE EXPRESSIVE ANIMAL AND TEST PROCEDURE THAT USE THIS ANIMAL
CN101240325A (zh) 一种检测遗传基因修复能力的试剂盒
DE60038029D1 (de) Methoden und reagenzien zur in situ amplifizierung
Henry Differentiation of allozyme loci to distinguish between two species of Eisenia
EP1446485A4 (en) DIAGNOSIS PROCEDURE FOR CANCER MARKED BY IDENTIFICATION OF THE DELETION OF THE G-CSF EXONS 3
WO2004005474A3 (en) A robust, inducible cardiac preferred expression system for transgenesis
Ledford CRISPR hack transform s cells into data recorders
Friedberg et al. Calculation and verification of the ages of retroprocessed pseudogenes
Basset et al. Identification of three Sorex species with microsatellite markers
Hecht Sequence analysis of Pmel17 as candidate gene for causing rat-tail syndrome in cattle